Compare Teradyne, Inc. (TER) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Zoetis Inc — how do they compare? Teradyne, Inc. trades at $400.83 (market cap $59.34B), while Zoetis Inc trades at $73.72 (market cap $31.14B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| TER | ZTS | |
|---|---|---|
Market Cap | $59.34B | $31.14B |
Sector | Technology | Health |
52-Week High | $483.84 | $156.76 |
52-Week Low | $109.30 | $71.91 |
Enterprise Value | $59.09B | $38.70B |
Dividend Yield | 0.14% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) is trading at $402.65, up 10.28% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows robust fundamentals with record revenue of $1.3 billion in Q2, net income margin of 25.77%, and consistent earnings beats. Technical indicators suggest bullish momentum with the current price near resistance at $400, while analyst consensus remains strongly positive with a $481.63 price target.
Outlook remains positive driven by AI-led semiconductor test demand and robotics growth, though elevated valuation multiples (P/E 52.14) and market volatility present risks. The company's strong guidance and institutional support suggest continued upside potential, but investors should monitor competitive pressures in the semiconductor equipment sector.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
